Research programme: metabolic disease therapeutics - Second Genome

Drug Profile

Research programme: metabolic disease therapeutics - Second Genome

Latest Information Update: 10 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Second Genome
  • Developer Mayo Clinic; Pfizer; Second Genome
  • Class Peptides; Small molecules
  • Mechanism of Action Metagenome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Metabolic disorders; Obesity

Most Recent Events

  • 07 Oct 2014 Second Genome enters into a collaboration with Mayo Clinic Center to support development of therapeutics for multiple disease indications, including metabolic disorders
  • 07 Oct 2014 Early research in Metabolic disorders in USA (unspecified route)
  • 02 May 2014 Second Genome enters into a collaboration with Pfizer to support development of therapeutics for metabolic disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top